|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0023473,
umls-concept:C0029016,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0185117,
umls-concept:C0332293,
umls-concept:C0332325,
umls-concept:C0681842,
umls-concept:C0935989,
umls-concept:C1268567,
umls-concept:C1552913,
umls-concept:C2757011,
umls-concept:C2911684
|
|
pubmed:issue |
26
|
|
pubmed:dateCreated |
2010-12-24
|
|
pubmed:abstractText |
Activation of the EVI-1 oncogene has been reported in acute myeloid leukemia, chronic myeloid leukemia (CML) in blast crisis, and less commonly, in chronic-phase CML patients. We screened an unselected cohort of 75 chronic-phase CML patients who had failed imatinib for expression of EVI-1 and sought a correlation with subsequent outcome on the second-generation tyrosine kinase inhibitors dasatinib (n = 61) or nilotinib (n = 14). The 8 patients (10.7%) who expressed EVI-1 transcripts detectable by real-time polymerase chain reaction had significantly lower event-free survival, progression-free survival, and overall survival than patients with undetectable transcript. The predictive value of EVI-1 expression was validated in an independent cohort. In a multivariate analysis, EVI-1 expression status and the best cytogenetic response obtained on imatinib were the only independent predictors for overall survival, progression-free survival, and event-free survival. Our data suggest that screening for EVI-1 expression at the time of imatinib failure may predict for response to second-line TKI therapy and consequently aid clinical management.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/4-methyl-N-(3-(4-methylimidazol-1-yl...,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/MECOM protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors,
http://linkedlifedata.com/resource/pubmed/chemical/dasatinib,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:ApperleyJane FJF,
pubmed-author:ClarkRichard ERE,
pubmed-author:DaghistaniMustafaM,
pubmed-author:De MeloValeria AVA,
pubmed-author:ForoniLetiziaL,
pubmed-author:GerrardGarethG,
pubmed-author:GoldmanJohn MJM,
pubmed-author:KhorashadJamshid SorouriJS,
pubmed-author:MarinDavidD,
pubmed-author:MayPhilippa CPC,
pubmed-author:MilojkovicDraganaD,
pubmed-author:PaliompeisChristosC,
pubmed-author:ReidAlistair GAG,
pubmed-author:WangLihuiL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
23
|
|
pubmed:volume |
116
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6014-7
|
|
pubmed:meshHeading |
pubmed-meshheading:20855863-Blast Crisis,
pubmed-meshheading:20855863-DNA-Binding Proteins,
pubmed-meshheading:20855863-Drug Resistance, Neoplasm,
pubmed-meshheading:20855863-Female,
pubmed-meshheading:20855863-Humans,
pubmed-meshheading:20855863-In Situ Hybridization, Fluorescence,
pubmed-meshheading:20855863-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:20855863-Male,
pubmed-meshheading:20855863-Middle Aged,
pubmed-meshheading:20855863-Piperazines,
pubmed-meshheading:20855863-Prognosis,
pubmed-meshheading:20855863-Protein Kinase Inhibitors,
pubmed-meshheading:20855863-Protein-Tyrosine Kinases,
pubmed-meshheading:20855863-Proto-Oncogenes,
pubmed-meshheading:20855863-Pyrimidines,
pubmed-meshheading:20855863-RNA, Messenger,
pubmed-meshheading:20855863-RNA, Neoplasm,
pubmed-meshheading:20855863-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20855863-Salvage Therapy,
pubmed-meshheading:20855863-Survival Rate,
pubmed-meshheading:20855863-Thiazoles,
pubmed-meshheading:20855863-Transcription Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
|
|
pubmed:affiliation |
Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
